Skip to content

Prevention and Treatment of Hemodialysis Vascular Access Malfunction

Prevention and Treatment of Hemodialysis Vascular Access Malfunction

Status
Withdrawn
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00179192
Enrollment
0
Registered
2005-09-15
Start date
1998-05-31
Completion date
2006-10-31
Last updated
2015-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-Stage Renal Disease

Keywords

End Stage Renal Disease, ESRD, Chronic Maintenance Hemodialysis

Brief summary

Vascular access is considered the Achilles heel of the dialysis patient. It constitutes the largest single cause of morbidity in the chronic hemodialysis population, accounting for over 25% of hospitalizations at an estimated cost in the US of at least one billion dollars annually. Currently, complication free survival of vascular access ranges between 30-50% a year and multiple investigative efforts in this area have been initiated and are directed at prolonging the functional life of vascular accesses. It is not well established whether intervention prior to overt malfunction or thrombosis of the vascular access could reduce these complications and thereby improve the functional longevity of the access. Moreover, once accesses at potential risk are identified, it is not well established which method of intervention, Surgery vs. Angioplasty vs. Expectant Management, is superior in terms of clinical and financial outcome. The proposed study aims to determine whether early intervention of a vascular access determined to be at risk of malfunction and thrombosis improves the long term outcome and, specifically, which means of intervention is preferred.

Interventions

PROCEDUREangioplasty

angioplasty performed at the time of the angiogram; approach and technique to be determined by the interventional radiologist

PROCEDUREsurgery

surgical revision of patient's PTFE in a timely fashion not to exceed 72-96 hours after the angiogram; method of revision to be determined by the surgeon performing the procedure

Sponsors

Vanderbilt University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Subjects with End Stage Renal Disease on chronic maintenance hemodialysis 3 times per week 2. Have an arteriovenous (polytetrafluoroethylene) graft as vascular access 3. Have a venous stenosis between 30% and 70% as determined by angiogram

Exclusion criteria

1. Native arteriovenous fistula 2. Known previous vascular accesses complications, such as central vein stenosis, and multiple access surgeries \>4 3. Unwilling to participate 4. Allergy to iodine 5. Absolute contraindication for surgery (e.g. medical condition precludes anesthesia and surgery) 6. Known arterial limb stenosis or long vessel length venous stenosis which are unamenable to surgical or angioplasty techniques, respectively, and therefore prohibit randomization 7. Known hypercoagulable state

Design outcomes

Primary

MeasureTime frame
To test the hypothesis that early intervention of a vascular access determined to be at increased risk of malfunction and thrombosis improves the long-term access outcome versus standard of care.2 years

Secondary

MeasureTime frame
To determine which means of early intervention, surgery versus angioplasty, is medically and financially advantageous.2 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026